{"id":58558,"date":"2026-03-02T14:11:14","date_gmt":"2026-03-02T06:11:14","guid":{"rendered":"https:\/\/flcube.com\/?p=58558"},"modified":"2026-03-02T14:11:14","modified_gmt":"2026-03-02T06:11:14","slug":"ribo-life-sciences-pcsk9-sirna-rbd7022-enters-phase-iii-qilu-pharma-advances-cholesterol-lowering-drug","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58558","title":{"rendered":"Ribo Life Science&#8217;s PCSK9 siRNA RBD7022 Enters Phase III \u2013 Qilu Pharma Advances Cholesterol\u2011Lowering Drug"},"content":{"rendered":"\n<p><strong>Suzhou Ribo Life Science Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/6938:HKG\">HKG:\u202f6938<\/a>)<\/strong> announced that <strong>RBD7022 Injection<\/strong>, its <strong>independently developed siRNA drug targeting PCSK9<\/strong>, has completed <strong>public registration for Phase III clinical trials<\/strong> by collaborator <strong>Qilu Pharmaceutical Co., Ltd.<\/strong> The study is <strong>about to initiate<\/strong>, advancing the <strong>cholesterol\u2011lowering therapeutic<\/strong> toward potential regulatory approval in Greater China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-milestone\">Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938)<\/td><\/tr><tr><td><strong>Licensee\/Collaborator<\/strong><\/td><td>Qilu Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>RBD7022 Injection<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>siRNA (small interfering RNA) targeting PCSK9<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Phase III registration completed; trial initiation imminent<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Chinese mainland, Hong Kong, Macau (exclusive rights granted to Qilu)<\/td><\/tr><tr><td><strong>Licensing Date<\/strong><\/td><td>December\u202f2023<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-rbd7022\">Drug Profile \u2013 RBD7022<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td><strong>PCSK9 (proprotein convertase subtilisin\/kexin type 9)<\/strong><\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>siRNA\u2011mediated gene silencing \u2192 reduces PCSK9 protein levels<\/td><\/tr><tr><td><strong>Therapeutic Effect<\/strong><\/td><td>Lowers <strong>LDL cholesterol<\/strong> \u2192 reduces cardiovascular disease risk<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td><strong>siRNA therapeutic<\/strong> \u2013 long\u2011acting nucleic acid medicine<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Hypercholesterolemia, cardiovascular risk reduction<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pcsk9-pathway-context\">PCSK9 Pathway Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Function<\/th><\/tr><\/thead><tbody><tr><td><strong>PCSK9 Enzyme<\/strong><\/td><td>Regulates LDL receptor degradation; higher PCSK9 \u2192 higher LDL cholesterol<\/td><\/tr><tr><td><strong>siRNA Approach<\/strong><\/td><td>Silences PCSK9 gene expression \u2192 sustained LDL receptor preservation \u2192 LDL lowering<\/td><\/tr><tr><td><strong>Clinical Advantage<\/strong><\/td><td>Potential for <strong>quarterly or less frequent dosing<\/strong> vs. monoclonal antibody alternatives (Repatha, Praluent)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>siRNA Cardiovascular Entry:<\/strong> RBD7022 represents <strong>Ribo Life Science&#8217;s expansion from oncology\/rare disease into cardiovascular\/metabolic<\/strong>\u2014a larger therapeutic market with significant unmet need for convenient LDL\u2011lowering options.<\/li>\n\n\n\n<li><strong>Qilu Pharma Execution:<\/strong> The <strong>Phase III advancement<\/strong> validates Qilu&#8217;s <strong>development capabilities<\/strong> and commitment to the <strong>2023 licensing deal<\/strong>, positioning both companies for <strong>shared commercial success<\/strong> in Greater China.<\/li>\n\n\n\n<li><strong>PCSK9 Competition:<\/strong> RBD7022 enters a market with <strong>approved mAbs (Repatha, Praluent)<\/strong> and <strong>oral PCSK9 inhibitors<\/strong> in development; siRNA differentiation lies in <strong>dosing frequency and durability<\/strong>.<\/li>\n\n\n\n<li><strong>China Cardiovascular Burden:<\/strong> <strong>Hypercholesterolemia affects hundreds of millions<\/strong> in China; effective PCSK9 targeting addresses a <strong>major public health priority<\/strong> and reimbursement\u2011sensitive market.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>PCSK9 Market Size<\/strong><\/td><td>~\u202f$3\u20114\u202fbillion globally; growing with cardiovascular outcome data and expanded indications<\/td><\/tr><tr><td><strong>siRNA vs. mAb Differentiation<\/strong><\/td><td>Inclisiran (Novartis) approved in EU\/US with twice\u2011yearly dosing; RBD7022 could offer similar convenience advantage<\/td><\/tr><tr><td><strong>China Market Dynamics<\/strong><\/td><td>Domestic innovation prioritized; PCSK9 siRNA would be <strong>first\u2011in\u2011class Chinese\u2011developed<\/strong> option vs. imported competitors<\/td><\/tr><tr><td><strong>Qilu Pharma Positioning<\/strong><\/td><td>Leading Chinese pharma with cardiovascular franchise; RBD7022 complements existing lipid\u2011lowering portfolio<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase III enrollment, efficacy outcomes, and commercial potential for RBD7022. Actual results may differ due to risks including competitive pricing pressure, manufacturing scale\u2011up for siRNA production, and reimbursement negotiation challenges in China&#8217;s healthcare system.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030200058_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026030200058_c.\"><\/object><a id=\"wp-block-file--media-ec85c7ea-71e5-4523-9665-de4cc0c1e039\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030200058_c.pdf\">2026030200058_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030200058_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ec85c7ea-71e5-4523-9665-de4cc0c1e039\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938) announced that RBD7022 Injection, its independently developed siRNA&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,4524,208,1725,64],"class_list":["post-58558","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-6938","tag-qilu-pharmaceutical","tag-ribo-life-science","tag-rnai-aso"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ribo Life Science&#039;s PCSK9 siRNA RBD7022 Enters Phase III \u2013 Qilu Pharma Advances Cholesterol\u2011Lowering Drug - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938) announced that RBD7022 Injection, its independently developed siRNA drug targeting PCSK9, has completed public registration for Phase III clinical trials by collaborator Qilu Pharmaceutical Co., Ltd. The study is about to initiate, advancing the cholesterol\u2011lowering therapeutic toward potential regulatory approval in Greater China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58558\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ribo Life Science&#039;s PCSK9 siRNA RBD7022 Enters Phase III \u2013 Qilu Pharma Advances Cholesterol\u2011Lowering Drug\" \/>\n<meta property=\"og:description\" content=\"Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938) announced that RBD7022 Injection, its independently developed siRNA drug targeting PCSK9, has completed public registration for Phase III clinical trials by collaborator Qilu Pharmaceutical Co., Ltd. The study is about to initiate, advancing the cholesterol\u2011lowering therapeutic toward potential regulatory approval in Greater China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58558\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T06:11:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58558#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58558\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ribo Life Science&#8217;s PCSK9 siRNA RBD7022 Enters Phase III \u2013 Qilu Pharma Advances Cholesterol\u2011Lowering Drug\",\"datePublished\":\"2026-03-02T06:11:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58558\"},\"wordCount\":437,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 6938\",\"Qilu Pharmaceutical\",\"Ribo Life Science\",\"RNAi \\\/ ASO\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58558#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58558\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58558\",\"name\":\"Ribo Life Science's PCSK9 siRNA RBD7022 Enters Phase III \u2013 Qilu Pharma Advances Cholesterol\u2011Lowering Drug - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-02T06:11:14+00:00\",\"description\":\"Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938) announced that RBD7022 Injection, its independently developed siRNA drug targeting PCSK9, has completed public registration for Phase III clinical trials by collaborator Qilu Pharmaceutical Co., Ltd. The study is about to initiate, advancing the cholesterol\u2011lowering therapeutic toward potential regulatory approval in Greater China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58558#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58558\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58558#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ribo Life Science&#8217;s PCSK9 siRNA RBD7022 Enters Phase III \u2013 Qilu Pharma Advances Cholesterol\u2011Lowering Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ribo Life Science's PCSK9 siRNA RBD7022 Enters Phase III \u2013 Qilu Pharma Advances Cholesterol\u2011Lowering Drug - Insight, China&#039;s Pharmaceutical Industry","description":"Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938) announced that RBD7022 Injection, its independently developed siRNA drug targeting PCSK9, has completed public registration for Phase III clinical trials by collaborator Qilu Pharmaceutical Co., Ltd. The study is about to initiate, advancing the cholesterol\u2011lowering therapeutic toward potential regulatory approval in Greater China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58558","og_locale":"en_US","og_type":"article","og_title":"Ribo Life Science's PCSK9 siRNA RBD7022 Enters Phase III \u2013 Qilu Pharma Advances Cholesterol\u2011Lowering Drug","og_description":"Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938) announced that RBD7022 Injection, its independently developed siRNA drug targeting PCSK9, has completed public registration for Phase III clinical trials by collaborator Qilu Pharmaceutical Co., Ltd. The study is about to initiate, advancing the cholesterol\u2011lowering therapeutic toward potential regulatory approval in Greater China.","og_url":"https:\/\/flcube.com\/?p=58558","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-02T06:11:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58558#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58558"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ribo Life Science&#8217;s PCSK9 siRNA RBD7022 Enters Phase III \u2013 Qilu Pharma Advances Cholesterol\u2011Lowering Drug","datePublished":"2026-03-02T06:11:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58558"},"wordCount":437,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 6938","Qilu Pharmaceutical","Ribo Life Science","RNAi \/ ASO"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58558#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58558","url":"https:\/\/flcube.com\/?p=58558","name":"Ribo Life Science's PCSK9 siRNA RBD7022 Enters Phase III \u2013 Qilu Pharma Advances Cholesterol\u2011Lowering Drug - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-02T06:11:14+00:00","description":"Suzhou Ribo Life Science Co., Ltd. (HKG:\u202f6938) announced that RBD7022 Injection, its independently developed siRNA drug targeting PCSK9, has completed public registration for Phase III clinical trials by collaborator Qilu Pharmaceutical Co., Ltd. The study is about to initiate, advancing the cholesterol\u2011lowering therapeutic toward potential regulatory approval in Greater China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58558#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58558"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58558#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ribo Life Science&#8217;s PCSK9 siRNA RBD7022 Enters Phase III \u2013 Qilu Pharma Advances Cholesterol\u2011Lowering Drug"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58558"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58558\/revisions"}],"predecessor-version":[{"id":58562,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58558\/revisions\/58562"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}